Johan M. Spoor, Chief Executive Officer and Director of Perspective Therapeutics, Inc. (NASDAQ:CATX), filed a Form 4 on November 12, 2026, disclosing an open-market purchase of 47,000 shares of common stock on November 11, 2026.

Key Highlights

  • Purchase transaction: Spoor acquired 47,000 shares of Perspective Therapeutics common stock on November 11, 2026, with transaction code "P" (open-market purchase).
  • Weighted average price: The shares were acquired at a weighted average price of $0.8073 per share, with individual transaction prices ranging from $0.8007 to $0.8157, inclusive.
  • Direct ownership following transaction: Spoor directly holds 106,383 shares of common stock following the reported purchase.
  • Indirect holdings: Additional shares are held indirectly, including 5,400 shares by Spoor's IRA, 12,600 by a spouse's IRA, 1,000 by a spouse, 4,650 by Child #1, and 4,650 by Child #2.
  • Roles: The filing identifies Spoor as both a Director and Chief Executive Officer of the issuer.

Spoor's November 11 Purchase of Perspective Therapeutics Common Stock

According to the Form 4 filing, Johan M. Spoor, serving as Chief Executive Officer and Director of Perspective Therapeutics, Inc. (NASDAQ:CATX), purchased 47,000 shares of the company's common stock on November 11, 2026. The filing reports a weighted average price of $0.8073 per share, with the footnote disclosing that the shares were acquired across multiple transactions at prices ranging from $0.8007 to $0.8157, inclusive. The filing notes that Spoor undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the issuer, any securityholder, or SEC staff.

Following the reported transaction, Spoor directly holds 106,383 shares of Perspective Therapeutics common stock, according to the filing. In addition, the filing discloses indirect beneficial ownership of shares held through several accounts and family relationships: 5,400 shares held by his IRA, 12,600 shares held by an IRA of his spouse, 1,000 shares held by his spouse, 4,650 shares held by Child #1, and 4,650 shares held by Child #2. No derivative securities transactions were reported in the filing.

The Form 4 was signed by Chris Nenno as Attorney-in-Fact for Johan (Thijs) Spoor and was filed with the SEC on November 12, 2026, with November 11, 2026, listed as the date of the earliest transaction.

What Was Disclosed

Perspective Therapeutics CEO Johan M. Spoor disclosed an open-market purchase of 47,000 common shares at a weighted average price of $0.8073 on November 11, 2026, bringing his direct holdings to 106,383 shares, with additional indirect holdings across family and IRA accounts.